The efficacy of prostate ‐specific antigen screening: Impact of key components in the ERSPC and PLCO trials

CONCLUSIONSThe observed cancer mortality reduction in screening trials appears to be highly sensitive to trial protocol and practice settings. Accounting for these differences, the efficacy of PSA screening in the PLCO setting is not necessarily inconsistent with ERSPC results. Cancer 2017. © 2017 American Cancer Society.

Source: Cancer - December 6, 2017 Category: Cancer & Oncology Authors: Harry J. de Koning, Roman Gulati, Sue M. Moss, Jonas Hugosson, Paul F. Pinsky, Christine D. Berg, Anssi Auvinen, Gerald L. Andriole, Monique J. Roobol, E. David Crawford, Vera Nelen, Maciej Kwiatkowski, Marco Zappa, Marcos Luj án, Arnauld Villers, Tiago Tags: Original Article Source Type: research